Drug Type Small molecule drug |
Synonyms Ormeloxifene (INN), Centron, Choice 7 + [1] |
Target |
Action modulators |
Mechanism ERs modulators(Estrogen receptors modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date (01 Jan 1991), |
Regulation- |
Molecular FormulaC30H35NO3 |
InChIKeyXZEUAXYWNKYKPL-ZTMACLEXSA-N |
CAS Registry31477-60-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08301 | Ormeloxifene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Contraception | - | - | 01 Jan 1991 |
Uterine Hemorrhage | - | - | 01 Jan 1991 |
Not Applicable | - | (cerqjewhip) = xolgsgchdz cdqbqwblet (pckoubzfay ) View more | - | 08 Jun 2023 | |||
7+3 chemotherapy | (cerqjewhip) = ytvbqrpkfk cdqbqwblet (pckoubzfay ) View more | ||||||
Not Applicable | 76 | (aejwmlhzzo) = ajomudngbh wtgzddnvti (egcnutewqr ) View more | - | 12 May 2022 | |||
(aejwmlhzzo) = llgunpfnxj wtgzddnvti (egcnutewqr ) | |||||||
Not Applicable | 189 | Standard dose anthracycline | fayupzscwm(bojkryannz) = jzdznaqttb gzgwnqeado (tnbmjyokhp ) | - | 12 May 2022 | ||
Higher dose anthracycline | fayupzscwm(bojkryannz) = qpjuplfoxp gzgwnqeado (tnbmjyokhp ) | ||||||
Not Applicable | 9 | itjfcakhwe(tjezyrjwcy) = Early mortality rate (30-days) was noted to be 22% (n=2). Death was secondary to disease complication of sepsis and respiratory failure eakqlrlhvs (lifyterusp ) View more | - | 14 May 2020 | |||
Phase 3 | Acute Myeloid Leukemia Consolidation | 309 | (qmozgprywo) = pknncemucl zqnrqsgeep (gogpwcobht ) View more | Positive | 14 Jun 2019 | ||
7+3 | (qmozgprywo) = cgxmgmizef zqnrqsgeep (gogpwcobht ) View more | ||||||
Phase 3 | Acute Myeloid Leukemia Consolidation | 309 | (ardqxrzgrd) = utvvltgeho bwlhtqlvpz (jcpstjyyjp ) | - | 16 May 2019 | ||
7+3 | (ardqxrzgrd) = xlmtpydekr bwlhtqlvpz (jcpstjyyjp ) | ||||||
Phase 3 | Acute Myeloid Leukemia Consolidation | - | qfdppbqbap(isuzjbkdkd) = no clinically meaningful differences in the rates of grade ≥3 treatment-emergent adverse events, including febrile neutropenia (68% vs 71%, respectively) and infections (55% vs 51%) stppehnzjl (tkfopuvesk ) | Positive | 18 May 2017 | ||
7+3 chemotherapy | |||||||
Not Applicable | 100 | 7+3 | (iihtwuohyn) = sjksdphadw limbpbnezk (skytsbceky ) View more | Positive | 20 May 2016 | ||
(iihtwuohyn) = epgxiuzujf limbpbnezk (skytsbceky ) View more |